Novartis to acquire Avidity Biosciences.

Novartis, a Swiss multinational pharmaceutical company, agreed to acquire Avidity Biosciences, a biotechnology company focused on developing a new class of targeted RNA therapeutics. Financial terms are not disclosed. "Avidity has expanded the possibilities of what RNA therapeutics can deliver to patients by advancing innovative science and creating an organization with a strong commitment to providing access to our potential medicines. We are confident that this transaction with Novartis maximizes value for our investors and will support the global expansion of our neuroscience pipeline. I am incredibly proud of what we have created in close collaboration with the patient and clinical communities we serve, and I want to thank them and the Avidity team for their commitment and dedication,"  Sarah Boyce, Avidity President and CEO.